Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The date of dealing was September 12, 2023. The form indicates that Panmure Gordon made purchases of 61,236 0.1p ordinary shares at a highest price per unit of 0.0282 and a lowest price per unit of 0.0282. There were no sales of securities. The form does not disclose any cash-settled derivative transactions, stock-settled derivative transactions, or other dealings.

The form also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives. The contact name provided for further information is Lauren Riley, with a telephone number of 020 7886 2963.

This disclosure is made in accordance with Rule 8 of the Takeover Code and must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.